Alan P. Dine Named Director, Clinical Research of I-Flow Corporation; Dine Appointment Reflects I-Flow's Commitment to Clinical Research for ON-Q Pain Management System.

Business Editors

LAKE FOREST, Calif.--(BUSINESS WIRE)--Feb. 20, 2002

I-Flow Corporation (Nasdaq:IFLO) announced today that Alan P. Dine has been named to the new position of Director, Clinical Research.

Dine, 51, joins I-Flow after developing the clinical research program for I-Flow's ON-Q(R) Pain Management System as Senior Project Leader with Johnson & Johnson's (NYSE:JNJ) Ethicon Endo-Surgery, Inc. subsidiary. Previously he led successful pharmaceutical development programs at Pfizer Inc. (NYSE:PFE), spearheading the antifungal Diflican Phase III/IV program and the global registration of another antifungal, Sporonox, while working for another Johnson & Johnson company, Janssen Pharmaceutica. He also spent five years with Procter & Gamble (NYSE:PG) managing the post marketing research program for Asacol, the global leader in the ulcerative colitis therapy market.

"Alan Dine brings an impressive resume of clinical research accomplishments to I-Flow. With nearly 20 years of experience in such critical areas as outcomes studies, clinical training, FDA new product submissions, product evaluations and licensing, he is highly qualified for this new position. We are entering an extremely exciting period in I-Flow's growth and are very pleased to have Alan working with us to build our surgical site-specific anesthesia business. Alan's appointment to this new clinical research position underscores our commitment to clinical research in order to make the ON-Q Pain Management System the standard of care for post-operative pain control," said I-Flow Chairman, President and Chief Executive Officer Donald M. Earhart.

"Alan will be responsible for the global clinical research programs for I-Flow's portfolio of products as we are moving rapidly to capture a much larger share of the acute pain management market and develop the ON-Q technology to its full potential," Earhart continued.

A member of the Associates of Clinical Pharmacology, American Society for Microbiology and Drug Information Association, Dine holds a B.S. degree in Nursing from Wright State University and a B.S. degree in Biology from the University of Cincinnati.

Surgical Sales Force & Clinical Nurses Network

I-Flow also announced that it has completed hiring its direct surgical sales force and that the Company now has coverage in each of its territories throughout the United States. In addition, I-Flow established a nationwide network of clinical nurses to support customer implementation of the ON-Q.

ON-Q Clinical Trials

Noting that the results of the completed ON-Q clinical studies are very encouraging and that I-Flow expects to report the results of more studies, Earhart said, "The ON-Q is enrolled in more than 20 clinical studies focused on eight important surgical specialties, making I-Flow a leader in clinical research to prove the benefits for surgical site regional anesthesia."

In 2001 a clinical study conducted at The University of Iowa's Holden Comprehensive Cancer Center confirmed the efficacy of using the ON-Q to control post-operative pain in patients with gynecologic malignancy.

A Duke University Medical Center clinical study completed in 2000 showed that I-Flow's C-bloc(TM) for continuous nerve block applications significantly decreased pain scores and the use of narcotics for pain control after shoulder surgeries. This research proved that the use of regional anesthesia infusion devices like the ON-Q can help hospitals meet the pain standards established by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) that went into effect on January 1, 2001.

The efficacy of the ON-Q in a multi-modal approach to postoperative pain control was shown in a study conducted by Alan Thorson, M.D. of the Colon and Rectal Specialists of Omaha, Nebraska. Dr. Thorson found that the ON-Q markedly reduced the need for supplemental pain medication following colon resection and patients returned to their rooms much less sedated and were quicker to converse and ambulate than those without the ON-Q. In addition, there was a more rapid return of bowel function, a reduction in the length of hospital stays and no increase in the incidence of wound infection with the ON-Q. Those patients that had previously experienced post-operative pain frequently noted a significant improvement in pain management with the ON-Q.

About I-Flow

I-Flow Corporation (www.i-flowcorp.com) designs, develops and markets technically advanced drug delivery systems that are redefining the standard of care by providing life enhancing, cost effective solutions for pain management and infusion therapy.

Certain disclosures made by the Company in this report and in other reports and statements released by the Company are and will be forward-looking in nature, such as comments that express the Company's opinions about trends and factors which may impact future operating results. Disclosures that use words such as the Company "believes," "anticipates," or "expects" or use similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, which could cause actual results to differ from those expected, and readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to republish revised forward-looking statements to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures made by the Company in this report which seek to advise interested parties of the risks and other factors that affect the Company's business, as well as in the Company's periodic reports on Forms 10-K, 10-Q, and 8-K filed with the Securities and Exchange Commission. The risks affecting the Company's business include reliance on the success of the home health care industry, the reimbursement system currently in place and future changes to that system, competition in the industry, economic conditions in foreign countries, currency exchange rates, technological changes, product availability and the Company's efforts to rapidly build a substantial direct sales force. Any such forward-looking statements, whether made in this report or elsewhere, should be considered in context with the various disclosures made by the Company about its business.